Experienced leader with over 15 years in immunotherapy, oncology, antiviral and antibacterial drug discovery. Proven track record in bioanalytical assay development, team leadership, and successful collaborations with CROs.Leadership Led and supervised an interdisciplinary team of senior scientists, scientists, and research associates, driving progress in oncology and antiviral programs.Directed and managed the development of cell-free and cell-based bioanalytical assays for key oncology targets (e.g. CD73, PD-1, CCRs) and antiviral targets (influenza and SARS-CoV-2).Research and DevelopmentDeveloped, optimized and implemented a diverse range of assays, including receptor inhibition, cell migration, flow cytometry, and virus entry inhibition, significantly enhancing drug discovery and development pipelines.Designed and optimized pharmacokinetic (PK) assays to measure drug levels and anti-drug antibodies (ADAs) in plasma and urine, tailored to a variety of species, including those from human clinical trials.CollaborationsManaged and coordinated multi-year collaborations with contract research organizations (CROs), overseeing projects involving surface plasmon resonance (SPR) binding studies, and the development of polyclonal and monoclonal antibodies.Documentation and ComplianceProvided key contributions for regulatory submissions, including patent filings, FDA briefing books, investor presentations, and IND submissions for drug candidates including CBO421 (oncology) and CD388 (influenza), leading to regulatory approvals.Upheld rigorous standards for data integrity and record-keeping, ensuring accurate and up-to-date electronic notebook entries and compliance with regulatory requirements.